

<b>Report Title</b>	Integrated Quality & Performance Report – April 2021					
<b>Sponsoring Executive</b>	Dave Baker, Director of Partnerships and Innovation					
<b>Report Author</b>	Matthew Maguire, Associate Director of Performance & Strategic Insight					
<b>Meeting</b>	Public Board	<b>Date</b>	9 <sup>th</sup> June 2021			
<b>1. Suggested discussion points</b> <i>[two or three issues you consider the Board should focus on]</i>						
<p>Reporting March, Cancer remains our biggest access challenge. Latest IQPR data shows that our 62 day cancer performance including rare cancers improved from 61.7% to 71.3%. Latest public view data ranks 62 day cancer performance as 84/124 compared to 99/124 in February. For 2 week waits our performance dropped from 73.6% to 71.8% with public view data ranking us 120/124 compared to 115/124 last month.</p> <p>HSMR/SHMI remain high (SHMI 116<sup>th</sup>/124 reporting December). Both have increased since the introduction of Unity and then the pandemic (HSMR most impacted). Work continues around improved documentation with our external auditors helping to facilitate a discussion this month based on award winning work at another Trust. To improve our reporting we need an increased focus on implementation. A paper to Q&amp;S considered the impact of hospital acquired Covid infection on the HSMR. The 4-6 month National reporting lag around these mortality metrics means that we have not yet seen the impact of January peak on the HSMR.</p> <p>Key Outliers in month were: 2 falls with severe harm (D47 and Newton 5) and 1 never event in AMU (use of air instead of Oxygen – this is the fourth event in the last 12 months). In Imaging Urgent (GP) Reporting within 5 days reduced to 46.2%, this is ~30% reduction of where this metric was historically reporting. We have had 3 x 28 day patient breaches (2 x T&amp;O, 1 x Urology). For note: A further never event will be reported in May in Ophthalmology in relation to wrong site surgery on an eye muscle. A new form IQPR/Board level metrics aligned to the three 2025 strategic objectives is a topic of discussion for Private Board this afternoon.</p>						
<b>2. Alignment to 2020 Vision</b> <i>[indicate with an 'X' which Plan this paper supports]</i>						
Safety Plan	X	Public Health Plan		People Plan & Education Plan	X	
Quality Plan	X	Research and Development		Estates Plan		
Financial Plan	X	Digital Plan		Other <i>[specify in the paper]</i>		
<b>3. Previous consideration</b> <i>[where has this paper been previously discussed?]</i>						
WD5 Flash, OMC, PMC, CLE, Q&S						
<b>4. Recommendation(s)</b>						
The Committee is asked to:						
<b>a.</b>	Note the April performance.					
<b>b.</b>	Gain assurance that plans around Cancer and HSMR/SHMI are robust					
<b>5. Impact</b> <i>[indicate with an 'X' which governance initiatives this matter relates to and where shown elaborate]</i>						
Trust Risk Register	X	Numerous				
Board Assurance Framework	X	SBAF 11: Labour Supply and SBAF 14: Amenable Mortality				
Equality Impact Assessment	Is this required?	Y		N	X	If 'Y' date completed
Quality Impact Assessment	Is this required?	Y		N	X	If 'Y' date completed